Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly
about
Stroke prevention in atrial fibrillation: latest clinical trials and guidelinesEvidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesA review of the LARIAT device: insights from the cumulative clinical experienceThe HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysisAssessing the risk of recurrent venous thromboembolism--a practical approachPreventing bleeding and thromboembolic complications in atrial fibrillation patients undergoing surgeryRecurrent venous thromboembolism: what is the risk and how to prevent itPhenotyping bleedingCare transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safetyMajor Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk ScoresDetecting nonvalvular atrial fibrillation and anticoagulant therapy in cardioembolic ischemic stroke.Addressing Disparities in Stroke Prevention for Atrial Fibrillation: Educational Opportunities.[Choosing wisely recommendations in cardiology].Triple Antithrombotic Therapy after Percutaneous Coronary Intervention (PCI) in Patients with Indication for Oral Anticoagulation: Data from a Single Center RegistryExtra-pericardial tamponade following Wolf Mini-Maze procedure: a case report.The challenge of bleeding in antiphospholipid antibody-positive patients.Outcomes of anticoagulation therapy in patients with mental health conditions.Selection of patients for intra-arterial treatment for acute ischaemic stroke: development and validation of a clinical decision tool in two randomised trialsMajor themes for 2013 in cardiothoracic and vascular anaesthesia and intensive care.Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants.A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risksSafe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-makingMedication adherence: process for implementationLeft atrial appendage closure to prevent stroke in patients with atrial fibrillationPredictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis.A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timeNon-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialPatterns of warfarin use in subgroups of patients with atrial fibrillation: a cross-sectional analysis of 430 general practices in the United Kingdom.Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation.Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective.The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant TreatmentIncidence, clinical impact and risk of bleeding during oral anticoagulation therapyComprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference.The case for an elderly targeted stroke management.Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study.
P2860
Q24628390-97EBE585-6164-4B14-85AA-25C3BF15CE70Q24632951-668E33D5-C142-45AB-B613-7FED4B91BDAFQ24633053-41186569-48F6-4493-A321-F0589F1A8498Q26781162-ABD4B58E-EFD8-41AA-9758-B91C9B0B2E08Q26784497-5B89B712-FE64-40BF-9287-E264F7FDE3D6Q26796430-6DAAE324-07D7-4212-A8A7-5E16B7290AA7Q26801820-D7F3FB78-36BD-4862-8F4C-A93332AA3F2FQ26826847-077200AF-5CDE-4A9E-873E-3DC7B849F19CQ26830732-4DD773F0-3CA5-4C2A-8D48-B26DC54D7608Q27025527-0BAC97A2-4A4C-4059-91A8-5FF9868FAA56Q29544821-E77B5F7D-2C19-492A-82B0-C54D430942A0Q30249817-4642CCD3-D9E8-4EF8-AD9F-7F2A450B155BQ30300349-BA2ABC84-5A22-4CA3-9326-D4D1C8CF11B7Q30313178-A7D55915-E0B9-428F-8086-82DCA97D1E27Q31001917-77712C10-AF8B-4626-AA52-A6E8E4558903Q33166419-F6DDEA0F-A3CB-4A54-86D3-5146100F3203Q33419972-A5DD6893-B13E-4EA0-9B24-E91C036AC9A2Q33633124-62BC4847-F4F3-464E-80BC-A99C468C8437Q33641217-B42C9A7C-58CA-47BE-B8A1-302DF1EFF560Q33893282-6FAB6E5D-5EC2-4B6F-A5FC-E6DF5E7F34C4Q33936087-3ACD4966-00BE-4918-9C6E-E5B1506EE949Q33949244-43C1A615-0F99-46A1-9425-75F658912F1EQ33949571-445A4E1A-EB4A-45F6-A6A4-7FD8608B26A7Q34005496-F759178C-F8B8-41CC-82FD-7D96083C3FB3Q34080391-044D5736-33E9-4456-AA5F-E05E7D9CE428Q34150474-3DFAA6CB-20AC-41D5-B73B-3CA19D693710Q34571082-0A8E22AC-4E1A-4562-8008-0661CE29AFD6Q34672746-AFAF35CD-EF8E-4E9D-B1CA-279F66ABE3D4Q34694778-F47EDB80-D63B-4BF2-90A9-27018A24F8B9Q34712397-F5573DDB-3986-49F9-9128-1987E246143FQ35016262-3F0AA361-8026-4D82-9E60-468EF4AE3A47Q35118898-23A46136-C121-4BF7-8687-630792F35826Q35181596-14DD0CD8-5ECD-4443-B9EC-D91A324FB005Q35532385-BD6D081E-0FA5-428A-8939-DAD2EEEDA4A6Q35575180-B185438C-B63E-4134-B24F-7D6F4EBE1645Q35609742-201806C2-64E9-457E-A0B2-EA602B23D05CQ35641960-8B926D64-D106-45F9-8518-44E2B84D82F2Q35752573-BCC4018C-9E46-42AF-898B-4D305B8743FEQ35768553-30B023D5-E8B8-41D6-80C5-3CCFA4587346Q35806598-95347868-4085-4674-9F18-D8E367137070
P2860
Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Comparative validation of a no ...... sposition, Labile INR, Elderly
@ast
Comparative validation of a no ...... sposition, Labile INR, Elderly
@en
Comparative validation of a no ...... sposition, Labile INR, Elderly
@nl
type
label
Comparative validation of a no ...... sposition, Labile INR, Elderly
@ast
Comparative validation of a no ...... sposition, Labile INR, Elderly
@en
Comparative validation of a no ...... sposition, Labile INR, Elderly
@nl
prefLabel
Comparative validation of a no ...... sposition, Labile INR, Elderly
@ast
Comparative validation of a no ...... sposition, Labile INR, Elderly
@en
Comparative validation of a no ...... sposition, Labile INR, Elderly
@nl
P1476
Comparative validation of a no ...... sposition, Labile INR, Elderly
@en
P2093
Deirdre A Lane
Lars Frison
P304
P356
10.1016/J.JACC.2010.09.024
P407
P577
2010-11-24T00:00:00Z